- Home
- IIF vs SGMT Comparison
IIF vs SGMT Comparison
Compare IIF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIF
- SGMT
- Stock Information
- Founded
- IIF 1993
- SGMT 2006
- Country
- IIF United States
- SGMT United States
- Employees
- IIF N/A
- SGMT N/A
- Industry
- IIF Trusts Except Educational Religious and Charitable
- SGMT
- Sector
- IIF Finance
- SGMT
- Exchange
- IIF Nasdaq
- SGMT Nasdaq
- Market Cap
- IIF 265.3M
- SGMT 230.3M
- IPO Year
- IIF N/A
- SGMT 2023
- Fundamental
- Price
- IIF $26.95
- SGMT $6.89
- Analyst Decision
- IIF
- SGMT Strong Buy
- Analyst Count
- IIF 0
- SGMT 7
- Target Price
- IIF N/A
- SGMT $26.57
- AVG Volume (30 Days)
- IIF 45.4K
- SGMT 587.6K
- Earning Date
- IIF 01-01-0001
- SGMT 08-13-2025
- Dividend Yield
- IIF 13.94%
- SGMT N/A
- EPS Growth
- IIF N/A
- SGMT N/A
- EPS
- IIF N/A
- SGMT N/A
- Revenue
- IIF N/A
- SGMT N/A
- Revenue This Year
- IIF N/A
- SGMT N/A
- Revenue Next Year
- IIF N/A
- SGMT N/A
- P/E Ratio
- IIF N/A
- SGMT N/A
- Revenue Growth
- IIF N/A
- SGMT N/A
- 52 Week Low
- IIF $18.95
- SGMT $1.73
- 52 Week High
- IIF $24.41
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- IIF 49.44
- SGMT 36.93
- Support Level
- IIF $26.10
- SGMT $7.01
- Resistance Level
- IIF $27.53
- SGMT $7.68
- Average True Range (ATR)
- IIF 0.36
- SGMT 0.45
- MACD
- IIF 0.02
- SGMT -0.03
- Stochastic Oscillator
- IIF 53.72
- SGMT 26.58
About IIF Morgan Stanley India Investment Fund Inc.
Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investment in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.